HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma
- 2 October 2012
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 461 (5) , 521-530
Abstract
Members of the HER (ERBB) receptor protein tyrosine kinase family play an important role in regulating cellular division, proliferation, differentiation, and migration and have prognostic significance in a number of cancers. Here, we sought to define their role in extrahepatic cholangiocarcinoma (EHCC). HER2 and HER3 protein expression was studied in 230 EHCC cases using a tissue microarray and compared with clinicopathological variables, including the survival of EHCC patients. HER3 was predominantly localized to the cytoplasm, whereas HER2 exhibited a membranous expression pattern. Overexpression of HER2 and HER3 was observed in 6 % (13/224) and 39 % (90/230) of EHCCs, respectively. Membranous HER2 overexpression occurred more frequently in intraductal papillary neoplasms with an associated invasive carcinoma than in tubular adenocarcinomas (P = 0.02). HER3 protein was more commonly overexpressed in nodular and infiltrative than in papillary tumors (P = 0.03). HER3 overexpression was associated with decreased survival in both univariate (P = 0.01) and multivariate (P = 0.008) analyses, whereas HER2 overexpression was not associated with survival. HER2 and HER3 are overexpressed in subsets of EHCC patients. Notably, HER3 overexpression is correlated with decreased patient survival, suggesting that HER3 constitutes a prognostic factor as well as a potential candidate for targeted therapy.Keywords
This publication has 62 references indexed in Scilit:
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences, 2011
- Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyBritish Journal of Cancer, 2008
- The ERBB3 receptor in cancer and cancer gene therapyCancer Gene Therapy, 2008
- Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinomaBritish Journal of Cancer, 2007
- Targeting HER proteins in cancer therapy and the role of the non-target HER3British Journal of Cancer, 2007
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- CholangiocarcinomaAnnals of Surgery, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Cholangiocarcinoma: Modern advances in understanding a deadly old diseaseJournal of Hepatology, 2006
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006